PT - JOURNAL ARTICLE AU - Giulia Tini AU - Bruno Achutti Duso AU - Federica Bellerba AU - Federica Corso AU - Sara Gandini AU - Saverio Minucci AU - Piergiuseppe Pelicci AU - Luca Mazzarella TI - Semantic and geographical analysis of Covid-19 trials reveals a fragmented clinical research landscape likely to impair informativeness AID - 10.1101/2020.05.14.20101758 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.14.20101758 4099 - http://medrxiv.org/content/early/2020/05/19/2020.05.14.20101758.short 4100 - http://medrxiv.org/content/early/2020/05/19/2020.05.14.20101758.full AB - Background The unprecedented impact of the Covid-19 pandemics on modern society has ignited a “gold rush” for effective treatment and diagnostic strategies, with a significant diversion of economical, scientific and human resources towards dedicated clinical research. We aimed to describe trends in this rapidly changing landscape to inform adequate resource allocation.Methods We developed informatic tools (Covid Trial Monitor) to analyze in real time growth rate, geographical distribution and characteristics of Covid-19 related trials. We defined structured semantic ontologies with controlled vocabularies to categorize trial interventions, study endpoints and study designs. Data and analyses are publicly available at https://bioinfo.ieo.it/shiny/app/CovidCTResults We observe a clear prevalence of monocentric trials with highly heterogeneous endpoints and a significant disconnect between geographic distribution and disease prevalence, implying that most countries would need to recruit unrealistic percentages of their total prevalent cases to fulfill enrolment.Conclusions This geographically and methodologically incoherent growth sheds doubts on the actual feasibility of locally reaching target sample sizes and the probability of most of these trials providing reliable and transferable result. We call for the harmonization of clinical trial design criteria for Covid19 and the increased use of larger master protocols incorporating elements of adaptive designs. Covid Trial Monitor identifies critical issues in current Covid19-related clinical research and represents a useful resource for researchers and policymakers to improve the quality and efficiency of related trialsCompeting Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was received for this workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are made available at https://bioinfo.ieo.it/shiny/app/CovidCT